Cargando…

421. If at first you do not succeed…. Repeat SARS-COV2 PCR testing

BACKGROUND: Nucleic Acid Amplification Tests (NAATs) of nasopharyngeal specimens (NPS) have become standard for diagnosis of SARS-COV2. IDSA guidelines suggest repeat testing after 24–48 h when initially negative and clinical suspicion persists. We characterized patients from whom initial NPS were N...

Descripción completa

Detalles Bibliográficos
Autores principales: Shea, Stephanie M, Patel, Gopi, Schaefer, Sarah, Nowak, Michael D, Sordillo, Emilia Mia, Paniz-Mondolfi, Alberto, Gitman, Melissa R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776324/
http://dx.doi.org/10.1093/ofid/ofaa439.615
_version_ 1783630655919226880
author Shea, Stephanie M
Patel, Gopi
Schaefer, Sarah
Nowak, Michael D
Sordillo, Emilia Mia
Paniz-Mondolfi, Alberto
Gitman, Melissa R
author_facet Shea, Stephanie M
Patel, Gopi
Schaefer, Sarah
Nowak, Michael D
Sordillo, Emilia Mia
Paniz-Mondolfi, Alberto
Gitman, Melissa R
author_sort Shea, Stephanie M
collection PubMed
description BACKGROUND: Nucleic Acid Amplification Tests (NAATs) of nasopharyngeal specimens (NPS) have become standard for diagnosis of SARS-COV2. IDSA guidelines suggest repeat testing after 24–48 h when initially negative and clinical suspicion persists. We characterized patients from whom initial NPS were NAAT-negative, but repeats were NAAT-positive, in order to identify which patients might benefit from repeat NAAT for SARS-CoV-2, and the appropriate interval. METHODS: We conducted an IRB-approved retrospective review of laboratory and electronic medical record data for all patients evaluated for SARS-CoV-2 infection at the Mount Sinai Health System, whose initial NAATs were done between March 16 – March 30, 2020, and who were retested within one month. NAATs were performed on NPS in viral transport medium using the Roche Diagnostics cobas® 6800 SARS-CoV-2 Test. Baseline patient characteristics, clinical and radiographic findings were identified. RESULTS: Of 235 patients eligible for inclusion, 172 (70.5%) were initially NAAT-negative, and 118 (68.6%) remained NAAT-negative over 1 month follow up. 54 (31.4%) converted to NAAT-positive over the next 1-month. Of patients who became NAAT-positive, 31 (57.4%) were inpatients who converted results within a single admission; the average interval was 6d 7h between the NAAT-negative and NAAT-positive results, and the minimum interval was 10.5 h. Symptoms examined for correlation for conversion to NAAT-positive were: fever, cough, shortness of breath, and combined nausea/vomiting/diarrhea. Duration of symptoms reported at triage did not appear to affect time to conversion to NAAT-positive. No individual symptom was more likely to be associated with conversion to NAAT- positive. However, time to conversion to NAAT-positive was shorter for patients with multiple symptoms. In general, chest radiography (CXR) findings correlated with NAAT results; interval to NAAT-positive was shorter for patients with worsening CXR findings. CONCLUSION: Our data supports repeat testing in patients with multiple clinical symptoms suggestive of SARS CoV-2 infection and negative initial NP test results. Further studies are needed to determine the true clinical sensitivity and specificity of SARS-CoV-2 NAAT assays. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7776324
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77763242021-01-07 421. If at first you do not succeed…. Repeat SARS-COV2 PCR testing Shea, Stephanie M Patel, Gopi Schaefer, Sarah Nowak, Michael D Sordillo, Emilia Mia Paniz-Mondolfi, Alberto Gitman, Melissa R Open Forum Infect Dis Poster Abstracts BACKGROUND: Nucleic Acid Amplification Tests (NAATs) of nasopharyngeal specimens (NPS) have become standard for diagnosis of SARS-COV2. IDSA guidelines suggest repeat testing after 24–48 h when initially negative and clinical suspicion persists. We characterized patients from whom initial NPS were NAAT-negative, but repeats were NAAT-positive, in order to identify which patients might benefit from repeat NAAT for SARS-CoV-2, and the appropriate interval. METHODS: We conducted an IRB-approved retrospective review of laboratory and electronic medical record data for all patients evaluated for SARS-CoV-2 infection at the Mount Sinai Health System, whose initial NAATs were done between March 16 – March 30, 2020, and who were retested within one month. NAATs were performed on NPS in viral transport medium using the Roche Diagnostics cobas® 6800 SARS-CoV-2 Test. Baseline patient characteristics, clinical and radiographic findings were identified. RESULTS: Of 235 patients eligible for inclusion, 172 (70.5%) were initially NAAT-negative, and 118 (68.6%) remained NAAT-negative over 1 month follow up. 54 (31.4%) converted to NAAT-positive over the next 1-month. Of patients who became NAAT-positive, 31 (57.4%) were inpatients who converted results within a single admission; the average interval was 6d 7h between the NAAT-negative and NAAT-positive results, and the minimum interval was 10.5 h. Symptoms examined for correlation for conversion to NAAT-positive were: fever, cough, shortness of breath, and combined nausea/vomiting/diarrhea. Duration of symptoms reported at triage did not appear to affect time to conversion to NAAT-positive. No individual symptom was more likely to be associated with conversion to NAAT- positive. However, time to conversion to NAAT-positive was shorter for patients with multiple symptoms. In general, chest radiography (CXR) findings correlated with NAAT results; interval to NAAT-positive was shorter for patients with worsening CXR findings. CONCLUSION: Our data supports repeat testing in patients with multiple clinical symptoms suggestive of SARS CoV-2 infection and negative initial NP test results. Further studies are needed to determine the true clinical sensitivity and specificity of SARS-CoV-2 NAAT assays. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7776324/ http://dx.doi.org/10.1093/ofid/ofaa439.615 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Shea, Stephanie M
Patel, Gopi
Schaefer, Sarah
Nowak, Michael D
Sordillo, Emilia Mia
Paniz-Mondolfi, Alberto
Gitman, Melissa R
421. If at first you do not succeed…. Repeat SARS-COV2 PCR testing
title 421. If at first you do not succeed…. Repeat SARS-COV2 PCR testing
title_full 421. If at first you do not succeed…. Repeat SARS-COV2 PCR testing
title_fullStr 421. If at first you do not succeed…. Repeat SARS-COV2 PCR testing
title_full_unstemmed 421. If at first you do not succeed…. Repeat SARS-COV2 PCR testing
title_short 421. If at first you do not succeed…. Repeat SARS-COV2 PCR testing
title_sort 421. if at first you do not succeed…. repeat sars-cov2 pcr testing
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776324/
http://dx.doi.org/10.1093/ofid/ofaa439.615
work_keys_str_mv AT sheastephaniem 421ifatfirstyoudonotsucceedrepeatsarscov2pcrtesting
AT patelgopi 421ifatfirstyoudonotsucceedrepeatsarscov2pcrtesting
AT schaefersarah 421ifatfirstyoudonotsucceedrepeatsarscov2pcrtesting
AT nowakmichaeld 421ifatfirstyoudonotsucceedrepeatsarscov2pcrtesting
AT sordilloemiliamia 421ifatfirstyoudonotsucceedrepeatsarscov2pcrtesting
AT panizmondolfialberto 421ifatfirstyoudonotsucceedrepeatsarscov2pcrtesting
AT gitmanmelissar 421ifatfirstyoudonotsucceedrepeatsarscov2pcrtesting